Aligos Therapeutics, Inc.
ALGS
$7.22
-$0.43-5.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -153.47% | 75.80% | -63.75% | -413.44% | 223.59% |
| Total Depreciation and Amortization | 78.35% | 6.64% | -11.29% | 1.17% | -31.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 96.70% | -99.54% | 160.04% | 97.13% | -448.29% |
| Change in Net Operating Assets | 140.60% | -518.97% | 148.15% | -77.38% | 30.20% |
| Cash from Operations | -10.61% | -18.16% | -21.11% | 20.46% | 8.08% |
| Capital Expenditure | -60.47% | -228.57% | -642.31% | -1,457.14% | 37.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 179.50% | -109.65% | 359.29% | -198.28% | 50.30% |
| Cash from Investing | 179.27% | -110.12% | 358.58% | -198.57% | 50.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 93.02% | -100.00% | 93.75% | -- |
| Issuance of Common Stock | -- | -10.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.06% | 26.80% | -1,225.00% | -162.99% | 535,584.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -68.07% | -1,519.15% | 339.88% | -365.16% | 133.00% |